Protocol Builder
Pick a goal and a level to see the combinations people describe for it, with each dose's source and what the evidence shows. These are descriptions, not recommendations.
What's your primary goal?
Choose the goal that best describes what you want to achieve.
Higher levels add compounds. More compounds means more combinations nobody has tested, not better results.
What the protocol builder shows
Choose a goal and a level and the builder shows a combination of compounds, a schedule drawn week by week, and a card for each compound with its dose, frequency and route. It covers 27 combinations across nine goals. Every dose now says where it comes from: label for an approved product's own dose, trial for a dose used in published trials, and community for an amount that users report and no trial has tested. Of the 64 compound lines, 56 are community amounts, 6 are label doses and 2 are a trial dose.
The builder does not recommend anything. It describes what people say they use, and it says plainly how little of it has been studied.
What changed, and why
This tool used to promise "a research-backed peptide protocol recommendation". The protocols were not research-backed: their tips presented anecdotes as results, one called the most common combination "the most widely prescribed peptide combination in clinical practice" with no source, and several doses were simply wrong for the drugs that have labels. Tesamorelin was listed at 2 mg at bedtime for fat loss; its approved dose is 1.4 mg once daily, for excess abdominal fat in adults with HIV-associated lipodystrophy only.1 SS-31 was listed at 4 mg; the approved product, FORZINITY, is dosed at 40 mg, for Barth syndrome.2 Those figures now come from the labels.
Two compounds needed more than a new label. The fat-loss protocols were built around AOD-9604, and one tip said taking it fasted was "important for efficacy"; in its largest trial, 536 adults taking it for 24 weeks lost no significant weight, as its encyclopedia entry records. The cognition protocol included dihexa, which has never been tested in people and whose best-known mechanism paper has been retracted; it has been removed (1 line). The tips have been replaced by evidence notes: each compound's own one-line summary from its encyclopedia entry, and a note whenever a combination has never been tested.
How to read a protocol
Start with the evidence notes, not the schedule. For most compounds here, the note will tell you that the human evidence is small, short or absent, and no combination in the builder has been tested as a combination. A label dose tells you what an approved product's trials supported, for the condition it was approved for; it does not mean the same dose does anything for a different goal. PT-141 is the one compound whose label covers the goal it is listed under, and only for premenopausal women with acquired low sexual desire; its label allows no more than one dose in 24 hours and eight a month.3
The durations, such as 8 or 12 weeks, are community conventions too. The reconstitution calculator turns a dose into syringe units, and each compound's encyclopedia entry and dosage page give the sources behind the numbers.
What the levels mean
The beginner, intermediate and advanced levels add compounds: one at beginner, two or three at intermediate, three or four at advanced. That is the only thing that changes. An advanced protocol is not a better-studied one; it is a larger combination that nobody has tested, with more doses to get wrong and more side effects to tell apart. The interaction checker shows what is known about each pair, which for most pairs is that no study has tested it.
Where approved options exist
For some goals the builder lists, approved medicines exist, and they come with label doses tested in large trials: semaglutide and tirzepatide for weight management, tesamorelin for HIV-associated abdominal fat, bremelanotide for acquired low sexual desire in premenopausal women.1,3 Those are prescription medicines chosen with a clinician. Our semaglutide vs tirzepatide article covers the weight medicines and the trials that compared them.
Sources
- Theratechnologies Inc. EGRIFTA SV (tesamorelin) for injection, US prescribing information: 1.4 mg subcutaneously once daily; indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. DailyMed version of July 31, 2026, read September 30, 2026.
- Stealth BioTherapeutics. FORZINITY (elamipretide) injection, US prescribing information: 40 mg subcutaneously once daily; indicated for Barth syndrome. DailyMed version of December 12, 2025, read September 30, 2026.
- Cosette Pharmaceuticals. VYLEESI (bremelanotide) injection, US prescribing information: 1.75 mg as needed at least 45 minutes before anticipated sexual activity; no more than one dose within 24 hours and no more than 8 doses per month; indicated for premenopausal women with acquired, generalized hypoactive sexual desire disorder. DailyMed version of November 18, 2025, read September 30, 2026.
This explainer describes how the tool works and what its numbers rest on. It is not medical advice and does not recommend any dose or product.